Paclitaxel Enhances Antibody-dependent Cell-mediated Cytotoxicity of Trastuzumab by Rapid Recruitment of Natural Killer Cells in HER2-positive Breast Cancer

Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells

(2012) Timothy Kute et al.   OncoImmunology

Rapidly progressive colonic dysplasia/neoplasia in a series of treated lung cancer patients: Is paclitaxel involved?

(2012) Antarpreet Kaur et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines

(2011) D. M. Collins et al.   ANNALS OF ONCOLOGY

Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance to Trastuzumab in Breast Cancer

(2009) P. R. Pohlmann et al.   CLINICAL CANCER RESEARCH

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

(2008) Alessandra Beano et al.   Journal of Translational Medicine